Table 3.

Pharmacodynamic outcomes for secondary endpoint INS–AUC_0–1 h and INS–C_max

Parameter	Lixisenatide treatment group	Effect estimate vs placebo	90% confidence intervals	p‐value
INS–AUC0–1 h (pmol min L−1)	2.5 µg	−8648	−12,713, −4584	<0.001
	5 µg	−16,762	−20,848, −12,676	<0.001
	10 µg	−21,896	−25,936, −17,856	<0.001
	20 µg	−24,848	−29,078, −20,618	<0.001
INS–Cmax (pmol L−1)	2.5 µg	−101	−216, 15	NS
	5 µg	−277	−391, −164	<0.001
	10 µg	−428	−543, −314	<0.001
	20 µg	−388	−509, −268	<0.001
Parameter	Lixisenatide treatment group	Effect estimate between doses	90% confidence intervals	p‐value
INS–AUC0–1 h (pmol min L−1)	5 µg vs 2.5 µg	−8114	−12,173, −4055	0.001
	10 µg vs 2.5 µg	−13,248	−17,214, −9281	<0.001
	20 µg vs 2.5 µg	−16,200	−20,262, −12,137	<0.001
	10 µg vs 5 µg	−5134	−9170, −1098	0.038
	20 µg vs 5 µg	−8086	−12,322, −3850	0.002
	20 µg vs 10 µg	−2952	−7049, 1145	NS
INS–Cmax (pmol L−1)	5 µg vs 2.5 µg	−177	−289, −64	0.011
	10 µg vs 2.5 µg	−328	−440, −216	<0.001
	20 µg vs 2.5 µg	−288	−403, −173	<0.001
	10 µg vs 5 µg	−151	−263, −40	0.027
	20 µg vs 5 µg	−111	−229, 6	NS
	20 µg vs 10 µg	40	−76, 156	NS

AUC, area under the curve; C_max, maximum concentration; INS, insulin; NS, non‐significant p‐value.

Data are point estimates of treatment group differences with 90% confidence intervals for lixisenatide treatment groups (2.5, 5, 10 and 20 µg) versus placebo or between lixisenatide doses.